Circulating tumor cell clusters: Insights into tumour dissemination and metastasis

References

• Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;133:571–573.
   Google Scholar
• Massagué J, Obenauf AC. Metastatic colonization by circulating tumor cells. Nature. 2016;529(7586):298–306.
   PubMed Web of Science ®Google Scholar
• Fidler IJ. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer (1965).. 1973;9(3):223–227.
   PubMed Web of Science ®Google Scholar
• Liotta LA, Kleinerman J, Saldel GM. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976;36(3):889–894.
   PubMed Web of Science ®Google Scholar
• Cho EH, Wendel M, Luttgen M, et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012;9(1):016001.
   PubMed Web of Science ®Google Scholar
• Suo Y, Xie C, Zhu X, et al. Proportion of circulating tumor cell clusters increases during cancer metastasis. Cytometry Part A. 2017;91(3):250–253.
   PubMedGoogle Scholar
• Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110–1122.•• Key paper in the field highlighting the higher metastatic potential of CTC clusters compared to single CTCs
   PubMed Web of Science ®Google Scholar
• Harris TJ, Tepass U. Adherens junctions: from molecules to morphogenesis. Nat Rev Mol Cell Biol. 2010;11(7):502–514.
   PubMed Web of Science ®Google Scholar
• Gkountela S, Castro-Giner F, Szczerba BM, et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 2019;176(1–2):98–112. e14.
   PubMed Web of Science ®Google Scholar
• Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. science. 2013;339(6119):580–584.
   PubMed Web of Science ®Google Scholar
• Aceto N. Bring along your friends: homotypic and heterotypic circulating tumor cell clustering to accelerate metastasis. Biomed J. 2020;43(1):18–23.
   PubMed Web of Science ®Google Scholar
• Rianna C, Radmacher M, Kumar S. Direct evidence that tumor cells soften when navigating confined spaces. Mol Biol Cell. 2020;31(16):1726–1734
   PubMed Web of Science ®Google Scholar
• Moro A, Foresta E, Gasparini G, et al. Ameloblastic carcinoma of the maxilla: A case report and an updated review of the literature. Oncol Lett. 2016;12(6):4339–4350.
   PubMed Web of Science ®Google Scholar
• Au SH, Storey BD, Moore JC, et al. Clusters of circulating tumor cells traverse capillary-sized vessels. Proc Nat Acad Sci. 2016;113(18):4947–4952.•• An important paper demonstrating that CTC clusters can travel through narrow capillaries in a single-file and reform the cluster
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Sawabata N. Circulating tumor cells in lung cancer: cluster circulating tumor cells as hybrid epithelial-mesenchymal transition/mesenchymal-epithelial transition (E/M). J Thorac Dis. 2017;9(10):3547–3550.
   Google Scholar
• Lee JM, Dedhar S, Kalluri R, et al. The epithelial–mesenchymal transition: new insights in signaling, development, and disease. J cell Biol. 2006;172(7):973–981.
   PubMed Web of Science ®Google Scholar
• Zheng Q-M, Chen X-Y, Bao Q-F, et al. ILK enhances migration and invasion abilities of human endometrial stromal cells by facilitating the epithelial–mesenchymal transition. Gynecological Endocrinol. 2018;34(12):1091–1096.
   PubMed Web of Science ®Google Scholar
• Van Es JH, Barker N, Clevers H. You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev. 2003;13(1):28–33.
   PubMed Web of Science ®Google Scholar
• Thompson EW, Newgreen DF. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 2005;65(14):5991–5995.
   PubMed Web of Science ®Google Scholar
• Zavadil J, Böttinger EP. TGF-β and epithelial-to-mesenchymal transitions. Oncogene. 2005;24(37):5764–5774.
   PubMed Web of Science ®Google Scholar
• Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004;90(3):561–565.
   PubMed Web of Science ®Google Scholar
• Thomas JR, Moore KM, Sproat C, et al. Integrin αVβ6-EGFR crosstalk regulates bidirectional force transmission and controls breast cancer invasion. bioRxiv. 2018;407908.
   Google Scholar
• Mani SA, Guo W, Liao M-J, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–715.
   PubMed Web of Science ®Google Scholar
• Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–273.
   PubMed Web of Science ®Google Scholar
• Yochum ZA, Cades J, Wang H, et al. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene. 2019;38(5):656–670.
   PubMed Web of Science ®Google Scholar
• Khoo BL, Warkiani ME, Tan DS-W, et al. Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. PloS One. 2014;9(7):e99409.
   PubMed Web of Science ®Google Scholar
• De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110.
   PubMed Web of Science ®Google Scholar
• Vetter M, Landin J, Szczerba BM, et al. Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer. Breast Cancer Res. 2018;20(1):141.
   PubMedGoogle Scholar
• Friedlander TW, Premasekharan G, Paris PL. Looking back, to the future of circulating tumor cells. Pharmacol Ther. 2014;142(3):271–280.
   PubMed Web of Science ®Google Scholar
• Szczerba BM, Castro-Giner F, Vetter M, et al. Neutrophils escort circulating tumor cells to enable cell cycle progression. Nature. 2019;566(7745):553–557.•• An important paper describing the composition of heterotypic CTC clusters and the presence of neutrophils within CTC clusters
   PubMed Web of Science ®Google Scholar
• Rostami P, Kashaninejad N, Moshksayan K, et al. Novel approaches in cancer management with circulating tumor cell clusters. J Sci. 2019;4(1):1–18.
   Web of Science ®Google Scholar
• Sprouse ML, Welte T, Boral D, et al. PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ROS/Notch/Nodal signaling. Int J Mol Sci. 2019;20(8):1916.
   Web of Science ®Google Scholar
• Cheung KJ, Padmanaban V, Silvestri V, et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Nat Acad Sci. 2016;113(7):E854–E863.
   PubMed Web of Science ®Google Scholar
• Brandt B, Junker R, Griwatz C, et al. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res. 1996;56(20):4556–4561.
   PubMed Web of Science ®Google Scholar
• Jansson S, Bendahl P-O, Larsson A-M, et al. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer. 2016;16(1):433.
   PubMedGoogle Scholar
• Murlidhar V, Reddy RM, Fouladdel S, et al. Poor prognosis indicated by venous circulating tumor cell clusters in early-stage lung cancers. Cancer Res. 2017;77(18):5194–5206.
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Chekhonin VP. Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme. Exp Mol Pathol. 2018;105(2):166–174.
   PubMed Web of Science ®Google Scholar
• Mego M, Gao H, Cohen EN, et al. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 2017 May 30;8(22):35656–35668. PubMed PMID: 27374101; PubMed Central PMCID: PMCPMC5482606. eng.
   PubMedGoogle Scholar
• Scheel C, Weinberg RA, Scheel C, et al., editors. Cancer stem cells and epithelial–mesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012;22:396–403. Elsevier.
   PubMed Web of Science ®Google Scholar
• Kim MS, Sim TS, Kim YJ, et al. SSA-MOA: a novel CTC isolation platform using selective size amplification (SSA) and a multi-obstacle architecture (MOA) filter. Lab Chip. 2012;12(16):2874–2880.
   PubMed Web of Science ®Google Scholar
• Luzzi KJ, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153(3):865–873.
   PubMed Web of Science ®Google Scholar
• Wang C, Mu Z, Chervoneva I, et al. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Cancer Res Treat. 2017;161(1):83–94.
   PubMed Web of Science ®Google Scholar
• Jacot W, Mazel M, Mollevi C, et al. Expression of PD-L1 on circulating breast cancer cells: correlation with clinicopathologic data and impact on prognosis. AACR. 2018;78(13 Suppl):Abstract nr 4589.
   Google Scholar
• Kulasinghe A, Perry C, Kenny L, et al. PD-L1 expressing circulating tumor cells in head and neck cancers. BMC Cancer. 2017;17(1):333.
   PubMedGoogle Scholar
• Brahmer J. PD-1-targeted immunotherapy: recent clinical findings. Clin Adv Hematol Oncol. 2012;10(10):674.
   PubMedGoogle Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Mazel M, Jacot W, Pantel K, et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015;9(9):1773–1782.
   PubMed Web of Science ®Google Scholar
• Strati A, Koutsodontis G, Papaxoinis G, et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann Oncol. 2017;28(8):1923–1933.
   PubMed Web of Science ®Google Scholar
• Tian M, Zhang Y, Liu Z, et al. The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats. Sci Rep. 2016;6(1):1–14.
   PubMedGoogle Scholar
• DiDomenico J, Lamano JB, Oyon D, et al. The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. Oncoimmunology. 2018;7(7):e1448329.
   PubMed Web of Science ®Google Scholar
• Lin A, Yan W-H. Human leukocyte antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol Med. 2015;21(1):782–791.
   PubMedGoogle Scholar
• Leblanc R, Peyruchaud O. Metastasis: new functional implications of platelets and megakaryocytes. Blood J Am Soc Hematol. 2016;128(1):24–31.
   Google Scholar
• Placke T, Örgel M, Schaller M, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–448.
   PubMed Web of Science ®Google Scholar
• Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell–mediated elimination of tumor cells. Blood. 2005;105(1):178–185.
   PubMed Web of Science ®Google Scholar
• Gruber I, Landenberger N, Staebler A, et al. Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. Anticancer Res. 2013;33(5):2233–2238.
   PubMed Web of Science ®Google Scholar
• Lou X-L, Sun J, Gong S-Q, et al. Interaction between circulating cancer cells and platelets: clinical implication. Chin J Cancer Res. 2015;27(5):450.
   PubMed Web of Science ®Google Scholar
• Piskounova E, Agathocleous M, Murphy MM, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015;527(7577):186–191.
   PubMed Web of Science ®Google Scholar
• Alix-Panabières C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. In: Minimal residual disease and circulating tumor cells in breast cancer. Vol. 195, Recent Results in Cancer Research. Berlin, Heidelberg: Springer; 2012. p. 69–76.
   Google Scholar
• Yu M, Stott S, Toner M, et al. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011;192(3):373–382.
   PubMed Web of Science ®Google Scholar
• Königsberg R, Obermayr E, Bises G, et al. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncologica. 2011;50(5):700–710.
   PubMed Web of Science ®Google Scholar
• Kulasinghe A, Zhou J, Kenny L, et al. Capture of circulating tumor cell clusters using straight microfluidic chips. Cancers (Basel). 2019;11(1):89.
   Web of Science ®Google Scholar
• Pantel K, Alix-Panabières C. Circulating tumor cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16(9):398–406.
   PubMed Web of Science ®Google Scholar
• Zeinali M, Lee M, Nadhan A, et al. High-throughput label-free isolation of heterogeneous circulating tumor cells and CTC clusters from non-small-cell lung cancer patients. Cancers (Basel). 2020;12(1):127.
   Web of Science ®Google Scholar
• Alix-Panabières C, Pantel K. Challenges in circulating tumor cell research. Nat Rev Cancer. 2014;14(9):623–631.
   PubMed Web of Science ®Google Scholar
• Poudineh M, Sargent EH, Pantel K, et al. Profiling circulating tumor cells and other biomarkers of invasive cancers. Nat Biomed Eng. 2018;2(2):72–84.
   PubMed Web of Science ®Google Scholar
• Alshareef M, Metrakos N, Juarez Perez E, et al. Separation of tumor cells with dielectrophoresis-based microfluidic chip. Biomicrofluidics. 2013;7(1):011803.
   PubMed Web of Science ®Google Scholar
• Tang Y, Shi J, Li S, et al. Microfluidic device with integrated microfilter of conical-shaped holes for high efficiency and high purity capture of circulating tumor cells. Sci Rep. 2014;4:6052.
   PubMed Web of Science ®Google Scholar
• Wan S, Kim TH, Smith KJ, et al. New labyrinth microfluidic device detects circulating tumor cells expressing cancer stem cell marker and circulating tumor microemboli in hepatocellular carcinoma. Sci Rep. 2019 Dec 09;9(1):18575.
   PubMedGoogle Scholar
• Fachin F, Spuhler P, Martel-Foley JM, et al. Monolithic chip for high-throughput blood cell depletion to sort rare circulating tumor cells. Sci Rep. 2017;7(1):1–11.
   PubMedGoogle Scholar
• Zhou J, Kulasinghe A, Bogseth A, et al. Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel. Microsys Nanoeng. 2019;5(1):1–12.
   PubMedGoogle Scholar
• Qian W, Zhang Y, Chen W. Capturing cancer: emerging microfluidic technologies for the capture and characterization of circulating tumor cells. Small. 2015;11(32):3850–3872.
   PubMed Web of Science ®Google Scholar